HIV-1 antigen-pulsed allogenic dendritic cells

HIV-1 antigen-pulsed allogeneic dendritic cells represent a type of cell therapy designed as a therapeutic vaccine for HIV-1 infection. This approach involves obtaining allogeneic dendritic cells (DCs) from a donor, typically an HLA-identical, HIV-seronegative individual. These donor DCs are then 'pulsed' or loaded with specific HIV-1 antigens, such as recombinant HIV-1 MN gp160 or synthetic peptides derived from HIV-1 envelope, Gag, and Pol proteins. The primary mechanism of action involves these antigen-presenting dendritic cells stimulating the recipient's immune system, particularly by activating cytotoxic T lymphocytes (CTLs) and enhancing lymphocyte-proliferative responses against HIV-1. The goal is to induce a robust, specific immune response capable of recognizing and potentially controlling HIV-infected cells, thereby enhancing the host's ability to fight the virus. Early pilot studies have investigated the safety and immunogenicity of this approach in HIV-infected patients.

Other names

allogeneic dendritic cell vaccine